AustraliaHealth

Imugene (ASX:IMU) announced exceptional clinical data from the CAR T-naïve cohort of its ongoing Phase 1b basket study of azer-cel.

Clarity Pharmaceuticals (ASX:CU6) has exceeded recruitment targets for its registrational Phase 3 AMPLIFY trial in just nine months.

Telix Pharmaceuticals (ASX:TLX) has met the primary objectives for Part 1 of its ProstACT Global Phase 3 study.

Global biotechnology firm CSL (ASX:CSL) has broken ground on a $1.5 billion expansion of its manufacturing facility in Kankakee.

Pro Medicus (ASX:PME) announced two major five-year contract renewals with a combined minimum value of $40 million.

Island Pharmaceuticals (ASX:ILA) has partnered with the Burnet Institute to expand its antiviral pipeline, targeting measles, chikungunya, and the Ross River virus.

New Zealand's Court of Appeal has dismissed an appeal by PBL Solutions regarding the entitlement to profits from AFT Pharmaceuticals' (ASX:AFP) topical skin treatment, Pascomer.

Embattled fertility giant Monash IVF Group (ASX:MVF) has reached an out-of-court settlement with families affected by two high-profile embryo mix-ups at its clinics in Brisbane and Melbourne.

Australian-Singaporean medtech leader Osteopore (ASX:OSX) signed a collaboration agreement with Tan Tock Seng Hospital.

CSL (ASX:CSL) has secured a major international contract to bolster Canada’s defences against future viral threats.

LTR Pharma (ASX:LTP) has completed recruitment for its Phase 2 pharmacokinetic clinical study of SPONTAN.

Island Pharmaceuticals (ASX:ILA) partners with USAMRIID and The Geneva Foundation to accelerate Galidesivir development for Marburg Virus Disease under the FDA Animal Rule.